New immunotherapy BPT567 tested in advanced cancer patients
Disease control
Terminated
This early-phase study tested a new drug called BPT567 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check the drug's safety and find the best dose. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Bright Peak Therapeutics Inc • Aim: Disease control
Last updated May 17, 2026 02:00 UTC